A specialty pharmaceutical company developing an improved approach to allergy immunotherapy for treating allergic diseases - no more shots
Allovate's product platform is AllerDent™, an improved and patient-friendly mode of immunotherapy (IT). IT is the only disease-modifying treatment that can address the underlying causes for the US's 60M allergy sufferers. A number of issues conspire to limit IT effectiveness, particularly compliance. AllerDent seamlessly integrates patients’ daily IT administration with the ritual of daily dental care (tooth brushing), a habitual behavior.